CMND news, real time CMND stock news, Clearmind Medici news today

News

1.240

-8.15%

-0.110

Clearmind Medicine announces additional safety results on CMND-100

TipRanks · 23h ago

Clearmind Medicine Announces Additional Safety Topline Results From Second Cohort Of Ongoing FDA-Approved Phase I/Iia Clinical Trial Evaluating CMND-100, Proprietary Non-Hallucinogenic MEAI-Based Oral Drug Candidate, For AUD Treatment

Benzinga · 23h ago

Clearmind Medicine meldet positive Sicherheitsergebnisse für CMND-100 in klinischer Studie gegen Alkoholabhängigkeit

Reuters · 23h ago

Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial

Reuters · 23h ago

CLEARMIND MEDICINE INC - SAFETY DATA SHOW NO SERIOUS ADVERSE EVENTS IN SECOND COHORT

Reuters · 23h ago

Weekly Report: what happened at CMND last week (0202-0206)?

Weekly Report · 1d ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Barchart · 1d ago

Clearmind Medicine kooperiert mit Polyrizon zur Entwicklung einer intranasalen MEAI-Formulierung

Reuters · 3d ago

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

NASDAQ · 3d ago

BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Reuters · 3d ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

TipRanks · 4d ago

Clearmind Engages Polyrizon To Apply Proprietary Intranasal Hydrogel Technology To Develop Optimized Formulation Of Clearmind's MEAI For Treatment Of Addiction-Related Disorders, Weight Loss And Other CNS Conditions

Benzinga · 4d ago

CLEARMIND MEDICINE ENTERS INTO DEVELOPMENT AGREEMENT TO ADVANCE INTRANASAL FORMULATION FOR ITS PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN MEAI

Reuters · 4d ago

Clearmind Medicine schließt Entwicklungsvereinbarung mit Polyrizon zur intranasalen Formulierung von MEAI

Reuters · 4d ago

Clearmind Medicine Signs Development Agreement with Polyrizon for Intranasal MEAI Formulation

Reuters · 4d ago

Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation

Reuters · 4d ago

POLYRIZON SIGNS AN AGREEMENT TO DEVELOP INTRANASAL PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN FORMULATION

Reuters · 4d ago

Psychedelic: Analyst initiates Definium, Helus with Buy ratings

TipRanks · 4d ago

Clearmind Medicine gibt Ausgabe von Wandelanleihen im Gesamtwert von 2,5 Millionen US-Dollar bekannt

Reuters · 5d ago

Clearmind Medicine Issues $2.5 Million in Convertible Promissory Notes

Reuters · 5d ago

Webull provides a variety of real-time CMND stock news. You can receive the latest news about Clearmind Medici through multiple platforms. This information may help you make smarter investment decisions.

About CMND

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.